Pulmonary hypertension and right ventricular failure. Part XII. Nitrous oxide and phosphodiesterase inhibitors in the treatment of primary pulmonary arterial hypertension

Batyraliev T. A., Makhmutkhodzhaev S. A., Ekinci E., Pataraya S. A., Pershukov I. V., Sidorenko B. A., ...Daha Fazla

KARDIOLOGIYA, cilt.47, sa.8, ss.76-86, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 47 Sayı: 8
  • Basım Tarihi: 2007
  • Dergi Adı: KARDIOLOGIYA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.76-86
  • Gazi Üniversitesi Adresli: Hayır

Özet

In a series of articles the authors discuss literature data concerning epidemiology of pulmonary arterial hypertension (PAH), its modern classification; peculiarities of its pathogenesis and treatment in various diseases and conditions. The twelfth communication contains consideration of inhaled nitrous oxide and three available inhibitors of phosphodiesterase type 5 (sildenafil, tadalafil, and vardenafil). The place of nitrous oxide in diagnostics and short term treatment of PAH is discussed.Analysis,of results of randomized controlled studies assessing efficacy and safety of sildenafil inpatients with primary (idiopathic) PAH an PAH associate wit connective tissue diseases and congenital heart diseases with systemic-to-pulmonary shunts is presented.